ABT-737 ameliorates docetaxel resistance in triple negative breast cancer cell line.

Eunjoo HwangSeong-Hye HwangJongjin KimJin Hyun ParkSohee OhYoung A KimKi-Tae Hwang

Published in: Annals of surgical treatment and research (2018)

Combination of ABT-737 with docetaxel elicits synergistic therapeutic effect on MDA-MB-231, a TNBC cell line overexpressing Bcl-2, mainly by activating the intrinsic pathway of apoptosis. Therefore, adjunct of ABT-737 to docetaxel might be a new therapeutic option to overcome docetaxel resistance of TNBCs overexpressing Bcl-2.

Keyphrases

locally advanced
cell cycle arrest
cell death
endoplasmic reticulum stress
signaling pathway
squamous cell carcinoma
rectal cancer
mouse model
drug delivery